Stanley Shadid, MD
Family Medicine · Edmond, OKNPI 1386904183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $300,158 of the $362,902 with a category attached, or 82.7%. Lilly USA, LLC accounts for 95.8% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2020 at $72,017 and has fallen 97.5% since, to $1,785 in 2025. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,097 payments — averaging $330.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$348K
- Eli Lilly$5K
- Genentech USA, Inc.$3K
- AbbVie$835
- Pfizer$596
- Amgen$523
- plus $5K from 47 others
What the payments were for
- Consulting fees$14,2194%
- Speaking & faculty fees$300,15883%
- Travel & lodging$36,36710%
- Food & beverage$12,0723%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$362,902 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 179 | $225,049 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 78 | $70,973 |
| TrulicityDulaglutide | 40 | $49,862 |
| OzempicSemaglutide | 28 | $29,748 |
| EliquisApixaban | 36 | $26,830 |
| JardianceEmpagliflozin | 16 | $24,788 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $19,298 |
| WegovySemaglutide | 13 | $17,511 |
| MyrbetriqMirabegron | 16 | $17,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,227 |
| KerendiaFinerenone | 14 | $12,886 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $10,039 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,737 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,979 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 144 | $5,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $347,722 | $274,910219 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Spiriva Respimat | $449 | $112,779119 claims |
| Novo NordiskOzempic, Wegovy | $378 | $47,25941 claims |
| PfizerEliquis, Dilantin | $596 | $28,51947 claims |
| MerckJanumet, Belsomra | $49 | $24,27829 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $214 | $23,96541 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $17,09116 claims |
| BayerKerendia | $374 | $12,88614 claims |
| AstraZenecaSymbicort | $418 | $2,89811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Susan DimickEdmond$28K
- Charles WoodwardEdmond$15K
- Darrel StoutEdmond$13K
- Christopher HayesEdmond$13K
- Jerimiah JohnsonEdmond$12K
- Alexander FrankOklahoma City$3.1M
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.